Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDMA Suggests Changes To Proposed Disease Definition

This article was originally published in The Tan Sheet

Executive Summary

The Nonprescription Drug Manufacturers Association, in Sept. 24 comments on FDA's proposed structure/function claims rules, suggests FDA modify its definition of "disease" to more closely fit within the scope of the Dietary Supplement Health & Education Act. "FDA's proposed definition of disease is overly expansive, by referencing 'any deviation from...normal structure or function,'" NDMA says.

You may also be interested in...



"Universal Changes" Like Aging Are "Natural," Not "Disease," States - GMA

"Universal changes," such as menopause and age-related decreases in sexual function, are "natural states" not subject to disease claims, the Grocery Manufacturers of America suggested at a public meeting on FDA's proposed rule on structure/function claims in Washington, D.C. Aug. 4.

"Universal Changes" Like Aging Are "Natural," Not "Disease," States - GMA

"Universal changes," such as menopause and age-related decreases in sexual function, are "natural states" not subject to disease claims, the Grocery Manufacturers of America suggested at a public meeting on FDA's proposed rule on structure/function claims in Washington, D.C. Aug. 4.

"Universal Changes" Like Aging Are "Natural," Not "Disease," States - GMA

"Universal changes," such as menopause and age-related decreases in sexual function, are "natural states" not subject to disease claims, the Grocery Manufacturers of America suggested at a public meeting on FDA's proposed rule on structure/function claims in Washington, D.C. Aug. 4.

Topics

UsernamePublicRestriction

Register

PS088896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel